Nephrology Nursing Insights for Managing Chronic Kidney Disease–associated Pruritus: Embracing Evolving Data and Emerging Agents to Optimize Outcomes


This educational activity will meet nephrology nurses where they are and provide them with expert insights into CKD-aP prevalence, patient burden, therapeutic rationale, and pivotal principles for safely and effectively integrating novel treatments into practice. The role of the nurse as a premier patient-facing care provider will be emphasized throughout, and notable focus will be placed on CKD-aP symptom recognition, patient education, drug administration, and toxicity management.

Target Audience

Nephrology nurses and nurse practitioners.

Learning Objectives

  • Review the prevalence of chronic kidney disease–associated pruritus (CKD-aP), especially in patients on dialysis, and identify the importance of symptom recognition and diagnosis.
  • Describe the deleterious impact of CKD-aP on patient quality of life, sleep integrity, mental health, and overarching clinical outcomes.
  • Examine the etiology and pathophysiology of CKD-aP, with an emphasis on opioid receptor dysregulation as a novel treatment target.
  • Discuss the recent FDA approval of difelikefalin and evaluate the role of the nephrology nurse in patient education/counseling, drug administration, and mitigation and management of any treatment-related toxicities.
  • Use real-world patient cases to design evidence-supported strategies for the nephrology nurse to recognize CKD-aP symptoms, offer patient-centric education, and provide treatment support.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from Vifor Pharma.

Additional Information

PDF icon Handout and References2.89 MB
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 

  5 min    Welcome and Introductions/Pre-test
10 min    Nephrology Nursing Knowledge: The Prevalence, Pathophysiology, and Patient-centric Clinical Gravity of CKD-aP
20 min    Novel Approaches, Novel Outcomes: A Review of the Evidence-supported Rationale for Targeting Opioid Receptor Pathways in CKD-aP Management
15 min    Nephrology Nurse Notions on CKD-aP: Practical Principles of Patient-focused Care in Today’s Hospital or Dialysis Clinic
  5 min    Conversations with the Experts: Audience Q&A/Post-test

United States

Lisa Koester-Wiedemann, ANP, CNN-NP
Nephrology Nurse Practitioner
St. Louis, MO




It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Ellie Kelepouris MD, FACP, FAHA–has disclosed that she is on the speakers bureau for AstraZeneca and Vifor Pharma. She is also an advisor or consultant to Akebia Therapeutics, Inc., Boehringer Ingelheim, Lilly and Vifor Pharma.

Lisa Koester-Wiedemann, ANP, CNN-NP–has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:
Cherly Cress, RN–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff/Planners:
Erin Spencer, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CE request form, statements of credit for nurses will be issued within 30 business days.

Available Credit

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.